ATI Neurostimulation Program demonstrates clinical effectiveness in treating cluster headache Autonomic Systems, Inc best generic and branded medicines store . , the programmer of the ATI Neurostimulation Program designed for the treatment of severe headaches, today announced results of their medical study in cluster headaches, now released online in Cephalalgia. The robust, multi-center, randomized, placebo-controlled clinical study is the largest research performed with a medical gadget for cluster headache. The ATI Neurostimulation System carries a novel, miniaturized device that’s implanted using oral medical procedures, leaving zero visible scars externally. When a cluster is felt by the individual attack starting, they hold a remote controller up with their cheek to begin with the neurostimulation therapy.
The new program will take benefit of ATS’s proprietary programmable conveyance program technology, called Supertrak. The various orders, all received by ATS through the Company’s recently completed first one fourth, are scheduled to become delivered over the next 16 a few months. Related StoriesReducing hospital readmissions through Transitional Care: an interview with Rani KhetarpalApplying a high restaurant model to healthcare communications: an interview with Brandi Robinson, SanofiDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix’The medical device sector, and even more the self-use diagnostics market particularly, is growing rapidly and because of our specialized single – resource features, ATS is a direct beneficiary of this rapid expansion,’ said Klaus Woerner, ATS Chief and President Executive Officer.